GlassScriptPhysician profile
Emilie Cole
NPI 1457357931
$2,163.45
in general payments reported to CMS, 2019-2025
24 companies · $284 in 2025
The $284 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $196 · 2021: $265 · 2022: $315 · 2023: $318 · 2024: $539 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $481.61 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Ironshore Pharmaceuticals INC. | $378.33 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $294.59 | 2019-2025 | |
| Sanofi Pasteur INC. | $207.97 | 2019-2024 | |
| Glaxosmithkline, LLC. | $155.38 | 2019-2025 | Bexsero, Shingrix, Rotarix |
| Kaleo, INC. | $129.65 | 2019-2022 | |
| Cranial Technologies, INC | $112.53 | 2019-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $44.64 | 2025 | Jornay Pm |
| Alk-Abello, INC | $42.60 | 2025 | Neffy |
| Neos Therapeutics, LP | $41.87 | 2024 | Adzenys Xr-Odt |
| Vertical Pharmaceuticals, LLC | $37.28 | 2024 | Relexxii |
| Dermira, INC. | $24.29 | 2020 | |
| Adlon Therapeutics L.P. | $24.03 | 2020-2021 | |
| Neurelis, INC. | $19.77 | 2024 | Valtoco |
| Arbor Pharmaceuticals, INC. | $19.62 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $18.95 | 2021 | |
| Hologic Sales and Service, LLC | $18.70 | 2024 | Aptima |
| Aytu Biopharma, INC. | $17.90 | 2024 | Karbinal |
| Seqirus USA INC | $17.47 | 2022 | |
| Metacel Pharmaceuticals LLC | $17.36 | 2023 | Ozobax |
| Mylan Pharmaceuticals INC. | $17.17 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.03 | 2025 | Qelbree |
| Biogen, INC. | $13.97 | 2022 | |
| Phadia US INC. | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emilie Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.